NumFin

Abiomed, Inc.

Simbols: ABMD

NASDAQ

381.02

USD

Tirgus cena šodien

  • 126.8485

    P/E koeficients

  • -5.7181

    PEG koeficients

  • 17.18B

    MRK Cap

  • 0.00%

    DIV ienesīgums

Abiomed, Inc. (ABMD) Finanšu pārskati

Download
GadaCeturkšņa
LineārāLog
Diagrammā redzami noklusējuma skaitļi dinamikā attiecībā uz Abiomed, Inc. (ABMD). Uzņēmuma ieņēmumi rāda vidējo NaN M, kas ir NaN % gowth. Vidējā bruto peļņa par visu periodu ir NaN M, kas ir NaN %. Vidējais bruto peļņas koeficients ir NaN %. Uzņēmuma neto ienākumu pieaugums pagājušajā gadā ir NaN %, kas ir vienāds ar NaN % % vidēji visā uzņēmuma vēsturē.,

GadaCeturkšņa
10Y20Y30Y40Y

Bilance

Ledziļinoties uzņēmuma Abiomed, Inc. fiskālajā trajektorijā, mēs novērojam vidējo aktīvu pieaugumu. Interesanti, ka šis rādītājs ir , kas atspoguļo gan uzņēmuma augstākos, gan zemākos rādītājus. Salīdzinot ar iepriekšējo ceturksni, šis rādītājs tiek pielāgots . Atskats uz pagājušo gadu atklāj kopējās aktīvu izmaiņas NaN apmērā. Akcionāru vērtība, ko atspoguļo kopējais akcionāru pašu kapitāls, tiek novērtēta kā NaN pārskata valūtā. Šā aspekta izmaiņas gada laikā ir NaN%.

common:word.in-mln

USD
Growth
TTM202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996199519941993199219911990198919881987

balance-sheet.row.cash-and-short-term-investments

3092.52758.6583.7443.1
491.7
362.2
229.9
212.1
132
76.6
76.7
77.2
60.3
58.3
57.2
38.3
75.1
30.8
41.5
27.3
54.4
71.3
92.5
106.4
18.2
26.4
9.4
10.6
0.6
0.5
0.7
4.7
8.1
24.6
10.4
13.3
2.4

balance-sheet.row.short-term-investments

2452.62625.8351250.8
370.7
319.3
190.9
163.8
109.6
55.7
67.3
71.2
54.5
53.5
55.4
36.3
5.5
23
33.9
20.4
9.9
25.7
2
4.5
8.9
23.7
7.7
7.7
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

365.1490.697.284.7
90.8
70
54.1
42.8
31.8
24.4
22.9
20.5
15.4
13.5
15.7
14.1
10.9
8.9
8.6
6
5.4
7.3
10
6.7
6.4
5.4
4.8
2.6
1.8
1.7
0.8
0.6
0.7
0.7
0.8
0.5
0.2

balance-sheet.row.inventory

381.799481.190.1
80.9
50.2
34.9
26.7
16.8
13.9
14.9
11.1
7.5
9.2
14.8
17.4
8.6
4.9
3.9
2.7
2.9
4.2
3.7
3.5
2.9
2.3
1.8
1.7
1.4
2.2
1.5
0.9
1.2
1.1
0.9
0.6
0.4

balance-sheet.row.other-current-assets

145.1933.32618
13.7
11.8
8
6.8
39.6
3.1
2
1.7
1.5
1.7
0.8
1.7
1.8
1.9
1.2
1
0.9
0.8
0.8
0.5
0.3
0.2
0.2
0.1
3.9
2.7
9
13.8
14
0.2
0.1
0
0.4

balance-sheet.row.total-current-assets

3984.64976.5788635.9
677.2
494.3
327
288.4
220.1
118
116.6
110.5
84.7
82.7
88.5
71.5
96.4
46.4
55.2
37
63.6
83.7
107
117.1
27.8
34.3
16.2
15
7.7
7.1
12
20
24
26.6
12.2
14.4
3.4

balance-sheet.row.property-plant-equipment-net

827.51212203.2176.7
145
117.2
87.8
23.2
9.1
6.9
6.5
6.4
6.3
6.8
7.8
7.6
5.8
4.8
2.8
3.2
4
4.7
4.8
4
3.9
3.7
1.9
0.6
0.5
0.6
0.7
0.6
1.1
1.1
0.3
0.3
0.3

balance-sheet.row.goodwill

302.0576.878.632
32.6
35.8
31
33
31.5
38
35.4
36.8
38.9
37.2
31.3
31.6
26.7
19.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

190.6345.647.522.6
15.2
16.7
14.5
15.4
14.7
0
0
0.1
1.6
3
4.4
6.9
7.3
8.2
0.9
0.8
0.7
0
0
0
0
0
0
0
0
0.1
0.2
0.2
0.3
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

492.68122.412654.5
47.8
52.5
45.5
48.4
46.2
38
35.4
37
40.6
40.1
35.7
38.5
34
27.3
0.9
0.8
0.7
0
0
0
0
0
0
0
0
0.1
0.2
0.2
0.3
0
0
0
0

balance-sheet.row.long-term-investments

1311.42351.9365.7302.2
21.7
37.5
47.1
1
14
41.8
11.4
0
0
0
3.7
0
0
0
2.1
18.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

50.2110.611.443.3
77.5
70.7
34.7
58.5
45.2
0
0
0
0
0
0
0
0
0.3
-2.1
-18.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

0003.8
85.1
14.2
8.3
4.4
3.7
0.8
0
0
0
0
0.3
0.5
0
-0.3
2.1
18.2
0
1.1
6.3
0.7
1.3
0.6
0.5
0.6
6.5
7.6
9.5
5
4.5
0
0
0
0

balance-sheet.row.total-non-current-assets

2681.81696.9706.4580.6
377.1
292.1
223.5
135.5
118.2
87.4
53.4
43.4
46.9
46.9
47.5
46.5
39.8
32.1
5.8
22.2
4.8
5.8
11
4.6
5.1
4.3
2.4
1.2
7
8.3
10.4
5.8
5.9
1.1
0.3
0.3
0.3

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

6666.451673.41494.41216.5
1054.3
786.4
550.4
423.9
338.4
205.4
170
153.9
131.6
129.6
136
118
136.2
78.5
61.1
59.2
68.3
89.5
118
121.8
33
38.6
18.5
16.2
14.7
15.4
22.4
25.8
29.9
27.7
12.5
14.7
3.7

balance-sheet.row.account-payables

137.2835.334.832.8
32.2
23.6
20.6
9.4
10.4
7.7
7.7
6.9
6.3
3.8
5.5
9
5.2
3.1
1.1
1.4
1.1
2
2.1
1.6
0.9
2.1
1.3
0.8
0.2
0.4
0.5
0.4
0.3
0
0
0
0

balance-sheet.row.short-term-debt

66.6706675.1
12.3
4.6
0.8
2.5
1.5
1.4
2.1
0.9
0
0
0
0
0
0
0
0
0
0.1
0.2
0.2
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-payables

20.021.95.921.6
12.3
4.6
3.2
2.5
1.5
1.4
2.1
0.9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

0000
0
0
15.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

Deferred Revenue Non Current

0000
0
0
-15.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

3---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

235.3176.73.84.9
45.2
41.6
37.7
25.9
20.4
16.5
13.1
11.5
14.1
13
10.8
9.3
7
5.2
3.6
3.3
4.2
5.6
5.6
6.4
4.8
2.9
2
1.5
1.2
0.7
0.7
0.8
0.6
1.3
1.2
1.2
1.4

balance-sheet.row.total-non-current-liabilities

114.1331.635.719.1
11.5
12.2
28.7
8.6
7.5
6.6
5.9
5.2
4.5
3.5
2.4
5
1.2
0.3
0
0
0
0
0.4
0.7
0.2
0.7
0
0
0
3.7
8.7
8.3
7.8
0
0
0
-0.1

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

0000
0
0
16.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

654.2170.1164.7151
117.5
96.9
98.3
55.2
46.8
37.1
32.9
27.6
26.8
21.6
20
24.4
14.1
9
4.9
4.8
6.2
10.2
9.3
8.9
5.9
5.6
3.3
2.3
1.4
4.8
9.9
9.5
8.7
1.3
1.2
1.2
1.3

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

1.820.50.50.5
0.5
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.3
0.3
0.3
0.2
0.2
0.2
0.2
0.2
0.1
0.1
0.1
0.1
0.1
0
0
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

4012.96964.5828602.5
399.5
140.5
-47
-99.1
-137.2
-250.9
-258.3
-273.3
-274.8
-263
-244
-212.4
-171.2
-143.3
-113.9
-111.5
-102.1
-84.4
-53.1
-41.7
-31.2
-24.5
-22
-22.8
-23.2
-22.9
-20.9
-17
-11.9
-5.3
-3.4
-1.1
-0.6

balance-sheet.row.accumulated-other-comprehensive-income-loss

-132.56-27.2-11.4-11.2
-14.7
-4.2
-20.6
-14.5
-17.3
-0.7
-3.7
-1.8
0.7
-1
-1.7
5
0.6
-2.1
-0.3
-0.1
-8.6
3.1
3.1
-5.4
-3.9
-2.7
-2.6
-2.3
-2.1
-1.9
-1.6
-1.4
-1.1
-0.8
-0.7
-0.5
-0.3

balance-sheet.row.other-total-stockholders-equity

2130.03565.5512.7473.7
551.7
552.8
519.2
482
445.7
419.6
398.7
400.9
378.4
371.6
361.3
300.7
292.4
214.6
170.1
165.7
172.5
160.4
158.4
159.9
62.1
60.2
39.8
39
38.6
35.4
35
34.7
34.2
32.5
15.4
15.1
3.3

balance-sheet.row.total-stockholders-equity

6012.251503.31329.71065.5
936.9
689.5
452.1
368.8
291.6
168.4
137.1
126.3
104.7
108
116
93.6
122.1
69.5
56.2
54.3
62.1
79.3
108.7
112.9
27.1
33
15.2
13.9
13.3
10.6
12.5
16.3
21.2
26.4
11.3
13.5
2.4

balance-sheet.row.total-liabilities-and-stockholders-equity

6666.451673.41494.41216.5
1054.3
786.4
550.4
423.9
338.4
205.4
170
153.9
131.6
129.6
136
118
136.2
78.5
61.1
59.2
68.3
89.5
118
121.8
33
38.6
18.5
16.2
14.7
15.4
22.4
25.8
29.9
27.7
12.5
14.7
3.7

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

6012.251503.31329.71065.5
936.9
689.5
452.1
368.8
291.6
168.4
137.1
126.3
104.7
108
116
93.6
122.1
69.5
56.2
54.3
62.1
79.3
108.7
112.9
27.1
33
15.2
13.9
13.3
10.6
12.5
16.3
21.2
26.4
11.3
13.5
2.4

balance-sheet.row.total-liabilities-and-total-equity

6666.45---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

3764.04977.7716.7553
392.4
356.8
238.1
164.8
123.6
97.4
78.7
71.2
54.5
53.5
59.1
36.3
5.5
23
36
38.6
9.9
25.7
2
4.5
8.9
23.7
7.7
7.7
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-debt

0000
0
0
16.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.1
0.2
0.2
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-debt

-639.9-132.8-232.7-192.3
-121
-43
-22.7
-48.2
-22.4
-20.9
-9.5
-6
-5.8
-4.8
-1.8
-2
-69.6
-7.8
-7.6
-6.9
-44.6
-45.6
-90.2
-101.7
-9.3
-2.7
-1.6
-2.9
-0.6
-0.5
-0.7
-4.7
-8.1
-24.6
-10.4
-13.3
-2.4

Naudas plūsmas pārskats

Abiomed, Inc. finanšu ainavā pēdējā laikā ir vērojamas ievērojamas izmaiņas brīvās naudas plūsmā, kas liecina par NaN pārmaiņām. Uzņēmums nesen palielināja savu pamatkapitālu, emitējot NaN, kas iezīmē NaN atšķirību salīdzinājumā ar iepriekšējo gadu. Uzņēmuma ieguldījumu darbības rezultātā neto naudas izlietojums pārskata valūtā sasniedza NaN. Tas ir NaN pieaugums salīdzinājumā ar iepriekšējo gadu. Tajā pašā periodā uzņēmums reģistrēja NaN, NaN un NaN, kas ir nozīmīgi, lai izprastu uzņēmuma ieguldījumu un atmaksas stratēģijas. Uzņēmuma finansēšanas darbības rezultātā neto naudas izlietojums bija NaN, un gada griezumā starpība bija NaN. Turklāt uzņēmums piešķīra NaN dividendēm akcionāriem. Tajā pašā laikā tas veica citus finanšu manevrus, kas minēti kā NaN, kas arī būtiski ietekmēja tā naudas plūsmu šajā periodā. Šīs sastāvdaļas kopā veido visaptverošu priekšstatu par uzņēmuma finansiālo stāvokli un stratēģisko pieeju naudas plūsmas pārvaldībai.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000199919981997199619951994199319921991

cash-flows.row.net-income

266.76136.5225.5203
259
112.2
52.1
38.1
113.7
7.4
15
1.5
-11.8
-19
-31.6
-40.9
-27.9
-29.4
-2.3
-9.4
-18.2
-21.7
-11.4
-10.5
-6.7
-2.5
0.7
0.5
-0.4
-2
-3.9
-5.1
-6.6

cash-flows.row.depreciation-and-amortization

27.5628.124.120.4
14.1
11
6.2
3.3
2.8
2.5
2.7
4.3
3.9
4.9
5
6.1
3.9
2.7
1.2
1.4
1.7
1.8
3
1.7
1.4
0.9
0.4
0.3
0.4
0.3
0.3
0.6
0.3

cash-flows.row.deferred-income-tax

-13.22.429.433
-7.7
42.6
25.8
22.3
-87.1
0.9
0.8
0.8
1
1
0.7
0.5
0.5
0.3
-0.1
-0.1
-0.1
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

53.7552.74739.8
54.5
40.4
32.9
29.1
16.5
11.2
9.5
7.8
5.4
5.4
8.8
5.4
5.8
0.4
0.1
0.1
0.1
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

-23.26-30.2-17.48
-38.8
-18.9
5.3
-15.6
-4.7
-0.5
-2.8
-11.7
0.5
3.6
-3.5
-8
-2.5
2.8
-4.1
-2.1
-0.2
-0.4
-3.5
1.5
-2.1
0.9
-1.4
-0.3
1.1
-1.8
-0.8
0.9
-0.7

cash-flows.row.account-receivables

-8.515.3-12.15.6
-22
-15.3
-11.6
-10.9
-8
-1.3
-2.6
-5.3
-1.9
2.2
-2.5
-2.8
-1.9
0.3
-2.6
-0.6
1.5
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-36-29.32.5-13.2
-37.2
-15.7
-12.3
-11.5
-7
-0.6
-5.3
-6.2
-1.5
0.9
-1.6
-11.1
-4.1
-0.2
-1.2
0.2
1.4
-0.7
-0.1
-0.7
-0.6
-0.9
-0.2
-0.2
0.8
-0.7
-0.7
0.3
-0.1

cash-flows.row.account-payables

8.480.62.62.6
8
4.4
7.6
-2.6
3.4
-0.1
1.2
0.3
2.5
-1.4
-2.4
3.2
1.6
1.3
-0.2
0.3
-0.9
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

12.77-6.8-10.513.1
12.4
7.6
21.6
9.4
6.8
1.5
3.9
-0.5
1.4
1.8
3
2.6
2
1.4
-0.2
-2
-2.1
0.3
-3.4
2.1
-1.5
1.8
-1.2
0
0.3
-1.1
-0.1
0.6
-0.6

cash-flows.row.other-non-cash-items

-60.6395.8-3410.7
-28.8
5.3
-7.2
-0.4
2.1
2.1
1.2
1
2.5
-3.1
2.2
8.1
0.3
13.9
0.1
0
0.5
0.3
0
0
0
0
0
0
-0.2
0.1
0.1
0.2
3

cash-flows.row.net-cash-provided-by-operating-activities

250.98000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-33.76-35.8-53.4-44
-44
-55.9
-50.4
-15.6
-5.2
-2.8
-2.8
-1.7
-1.8
-1.8
-3.8
-3.8
-2.4
-3.1
-0.7
-0.4
-0.8
-1.6
-2.6
-1.4
-1.6
-16
-1.6
-0.3
-0.1
-0.2
-0.3
-0.1
-0.2

cash-flows.row.acquisitions-net

0-82.8-52.20
0
0
0
0
-15.7
0
0
1.7
3.8
4.6
5.6
0
0
-2.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

-745.81-805.9-582.3-632.2
-404.3
-331.8
-281.4
-261.7
-100.5
-87.8
-49.4
-24.5
-8
-11.9
-60.2
-66.4
-17.7
-29
-39.5
-39
-14.6
-38
-27
-8.3
-25.5
0
0
0
-1.3
-2.9
-4.3
0
0

cash-flows.row.sales-maturities-of-investments

616.66543.5464.5550.8
331.9
206.9
205.5
219.6
71.5
68.3
42
8.8
7
17.8
37.1
34.5
35.2
42
42.2
10.2
30.4
14.4
29.4
12.7
40.4
0
0
2.7
0
6.2
4.9
0
5.5

cash-flows.row.other-investing-activites

0000
0
0
0
0
0
0
0
-1.7
-3.4
0
-5.6
-5.1
0
0
0
0
-0.1
0
0
0
0
-2.5
0
-0.8
0.7
0
0.1
0
-0.1

cash-flows.row.net-cash-used-for-investing-activites

-162.91-381-223.3-125.5
-116.5
-180.8
-126.3
-57.7
-49.9
-22.3
-10.3
-17.5
-2.4
8.8
-26.8
-40.9
15.1
7.4
1.9
-29.2
14.8
-25.2
-0.1
3.1
13.3
-18.5
-1.6
1.6
-0.7
3.1
0.4
-0.1
5.2

cash-flows.row.debt-repayment

0000
0
-0.5
-0.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

10.357.25.55.1
3.1
2.4
1.7
1.1
0.8
-0.3
-0.3
0.4
0.3
0.3
42.2
3.9
66.6
2.2
4.1
1.6
0.3
1
0.9
96.3
0.8
20.3
0.5
0.1
0
0.1
0.1
0.1
1.4

cash-flows.row.common-stock-repurchased

-126.620-11.3-84.9
0
0
0
0
0
-0.4
-15.3
0
0
0
0
-1.9
-0.1
-0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

-19.26-9.4-2.2-37.9
-58.8
-11
2.6
6
8.7
10.3
3.7
14.3
1.1
0.6
4
0
0
0
0
0
-0.1
-0.5
-0.2
0.6
0
0
0
0
0
0
-0.1
0
0

cash-flows.row.net-cash-used-provided-by-financing-activities

-135.53-2.2-8.1-117.7
-55.8
-9.1
3.9
7.2
9.5
9.6
-11.8
14.7
1.4
1
46.2
2.1
66.6
2.1
4.1
1.6
0.3
0.5
0.6
96.9
0.8
20.3
0.5
0.1
0
0.1
0
0.1
1.4

cash-flows.row.effect-of-forex-changes-on-cash

-12.08-2.1-2.8-0.4
-1.9
1.3
-1.8
-0.4
-1.5
0.6
-0.9
-0.7
0.4
0.6
-1.4
0.1
0
0.1
-0.1
0.1
0
0
0
0
0
0
0
0
0
0.3
0
3.5
-1.2

cash-flows.row.net-change-in-cash

-59.55-99.940.471.3
78
3.9
-9.2
25.8
1.5
11.5
3.5
0.2
1
3
-0.3
-67.6
61.8
0.2
0.8
-37.7
-1.1
-44.8
-11.5
92.6
6.6
1.1
-1.3
2.3
0.2
0.1
-3.9
0.1
1.4

cash-flows.row.cash-at-end-of-period

639.9132.8232.7192.3
121
43
39
48.2
22.4
20.9
9.5
6
5.8
4.8
1.8
2
69.6
7.8
7.6
6.9
44.6
45.7
90.5
101.9
9.3
2.7
1.6
2.9
0.7
0.8
0.8
8.1
6.8

cash-flows.row.cash-at-beginning-of-period

699.45232.7192.3121
43
39
48.2
22.4
20.9
9.5
6
5.8
4.8
1.8
2
69.6
7.8
7.6
6.8
44.6
45.7
90.5
101.9
9.3
2.7
1.6
2.9
0.6
0.5
0.7
4.7
8
5.4

cash-flows.row.operating-cash-flow

250.98285.4274.6314.9
252.2
192.5
115.1
76.8
43.3
23.5
26.4
3.6
1.6
-7.4
-18.3
-28.9
-19.8
-9.3
-5.2
-10.1
-16.2
-20.1
-12
-7.3
-7.4
-0.7
-0.2
0.6
0.9
-3.4
-4.3
-3.4
-4

cash-flows.row.capital-expenditure

-33.76-35.8-53.4-44
-44
-55.9
-50.4
-15.6
-5.2
-2.8
-2.8
-1.7
-1.8
-1.8
-3.8
-3.8
-2.4
-3.1
-0.7
-0.4
-0.8
-1.6
-2.6
-1.4
-1.6
-16
-1.6
-0.3
-0.1
-0.2
-0.3
-0.1
-0.2

cash-flows.row.free-cash-flow

217.22249.6221.2270.9
208.2
136.7
64.7
61.2
38.1
20.7
23.6
1.9
-0.2
-9.2
-22.1
-32.7
-22.2
-12.4
-5.9
-10.6
-17
-21.7
-14.5
-8.7
-9
-16.7
-1.8
0.2
0.8
-3.6
-4.6
-3.5
-4.2

Peļņas vai zaudējumu aprēķina rinda

Abiomed, Inc. ieņēmumi salīdzinājumā ar iepriekšējo periodu mainījās par NaN%. Tiek ziņots, ka ABMD bruto peļņa ir NaN. Uzņēmuma darbības izdevumi ir NaN, kas salīdzinājumā ar iepriekšējo gadu ir mainījušies par NaN%. Nolietojuma un amortizācijas izdevumi ir šādi NaN, kas ir NaN% izmaiņas salīdzinājumā ar iepriekšējo pārskata periodu. Tiek ziņots, ka darbības izdevumi ir NaN, kas uzrāda NaN% izmaiņas gada laikā. Pārdošanas un mārketinga izdevumi ir NaN, kas ir NaN% izmaiņas salīdzinājumā ar iepriekšējo gadu. EBITDA, pamatojoties uz jaunākajiem skaitļiem, ir NaN, kas veido NaN% pieaugumu salīdzinājumā ar iepriekšējo gadu. Pamatdarbības ienākumi ir NaN, kas uzrāda NaN% izmaiņas, salīdzinot ar iepriekšējo gadu. Tīro ienākumu izmaiņas ir NaN%. Pagājušā gada neto ienākumi bija NaN.

common:word.in-mln

USD
Growth
TTM202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996199519941993199219911990198919881987

income-statement-row.row.total-revenue

1074.11031.8847.5840.9
769.4
593.7
445.3
329.5
230.3
183.6
158.1
126.4
101.2
85.7
73.2
58.9
50.6
43.7
38.2
25.7
23.3
26.9
24.9
22.5
22.1
22.4
16.5
12.8
9.2
6.7
3.4
2.7
2
3
2.9
4.2
4.7

income-statement-row.row.cost-of-revenue

200.59188.2161.9151.3
129.6
98.6
70.6
50.4
39.9
37.3
31.6
24.5
22
22.5
20.4
15.1
12
11.7
9.4
7.6
7.5
7.9
7.4
5.9
6.8
6.5
5.4
3.9
2.9
1.9
3
2
1.3
1
1.1
0.2
3.7

income-statement-row.row.gross-profit

873.51843.6685.6689.6
639.9
495.2
374.7
279.1
190.4
146.3
126.5
101.9
79.2
63.2
52.8
43.9
38.6
32
28.9
18.1
15.8
18.9
17.5
16.6
15.3
15.9
11.1
8.9
6.3
4.8
0.4
0.7
0.7
2
1.8
4
1

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

167.22---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

-7.58051.9-4.6
30.4
-0.4
-0.3
0.3
-0.1
0
0.3
1.5
1.4
1.5
1.6
2.8
1.6
1.3
13.2
13.6
20.4
0
0
0
0
-1.2
0
0
0.4
0.3
0.3
0.6
0.3
0.2
0.2
0.2
0.2

income-statement-row.row.operating-expenses

619.4586.9456.1440.4
415.1
338
284.5
214
161.7
138
110
100.3
90.4
88.3
82.3
80.4
66.3
62.3
32.1
28.4
35.3
43.6
35.1
28.2
23.2
16.9
10.9
9
7.2
7.1
4.9
7
9.1
5.4
5
5.3
1.1

income-statement-row.row.cost-and-expenses

819.99775618591.7
544.6
436.6
355.2
264.4
201.6
175.3
141.6
124.9
112.3
110.8
102.7
95.4
78.4
74
41.5
36
42.8
51.5
42.5
34.1
30
23.4
16.3
12.9
10.1
9
7.9
9
10.4
6.4
6.1
5.5
4.8

income-statement-row.row.interest-income

94.2449.800
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

94.2449.800
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

87.06-182.158.77.6
38.5
3.3
1.2
0.7
0.1
0.2
0.3
1
0.3
6.7
-1.3
-5.1
0.3
0
0.1
0.2
0.2
0
0
0
0
0
0
0
0.4
0.4
0.6
1.2
1.7
1.5
0.9
0.7
0.2

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

-7.58051.9-4.6
30.4
-0.4
-0.3
0.3
-0.1
0
0.3
1.5
1.4
1.5
1.6
2.8
1.6
1.3
13.2
13.6
20.4
0
0
0
0
-1.2
0
0
0.4
0.3
0.3
0.6
0.3
0.2
0.2
0.2
0.2

income-statement-row.row.total-operating-expenses

87.06-182.158.77.6
38.5
3.3
1.2
0.7
0.1
0.2
0.3
1
0.3
6.7
-1.3
-5.1
0.3
0
0.1
0.2
0.2
0
0
0
0
0
0
0
0.4
0.4
0.6
1.2
1.7
1.5
0.9
0.7
0.2

income-statement-row.row.interest-expense

94.2449.800
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

30.4828.117.48.3
14.1
11
6.2
3.3
2.8
2.5
2.7
4.3
3.9
4.9
5
6.1
3.9
2.7
1.2
1.4
1.7
1.8
3
1.7
1.4
0.9
0.4
0.3
0.4
0.3
0.3
0.6
0.3
0.2
0.2
0.2
0.2

income-statement-row.row.ebitda-caps

284.19---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

253.61372.7229.6249.2
224.8
157.1
90.1
65.1
28.7
8.4
16.5
1.5
-11.2
-25.1
-29.5
-36.5
-28.5
-30.3
-3.3
-10.3
-19.5
-24.6
-17.6
-11.6
-7.9
-1
0.2
0
-0.9
-2.3
-4.5
-6.3
-8.4
-3.4
-3.2
-1.3
-0.1

income-statement-row.row.income-before-tax

341.16190.6288.2256.8
263.4
160.4
91.3
65.8
28.8
8.5
16.9
2.5
-10.9
-18.4
-30.8
-40.4
-27.4
-29.1
-2.3
-9.4
-18.2
0
0
0
0
0
0
0
-0.5
-1.9
-3.9
-5.1
-6.7
-1.9
-2.3
-0.6
0.1

income-statement-row.row.income-tax-expense

74.454.162.753.8
4.3
48.3
39.2
27.7
-84.9
1.2
1.8
1
0.9
0.7
0.8
0.5
0.5
0.4
0.1
0.2
0.2
-2.9
-6.2
-1.1
-1.2
1.5
-0.5
-0.5
-0.5
0.4
0.6
1.2
1.7
1.5
0.9
0.7
0.2

income-statement-row.row.net-income

266.76136.5225.5203
259
112.2
52.1
38.1
113.7
7.4
15
1.5
-11.8
-19
-31.6
-40.9
-27.9
-29.4
-2.3
-9.4
-18.2
-21.7
-11.4
-10.5
-6.7
-2.5
0.7
0.5
-0.4
-2
-3.9
-5.1
-6.6
-1.9
-2.2
-0.6
0.1
Līdzīgas akcijas
Jūs varētu arī interesēt:
EAR
Eargo, Inc..
2.58 USD
NASDAQ
ELEAF
EL.En. S.p.A..
9.8 USD
PNK
FORZ
Forza Innovations Inc..
0.0001 USD
PNK
SILK
Silk Road Medical, Inc.
18.97 USD
NASDAQ
UNIVPHOTO.NS
Universus Photo Imagings Limited.
391 INR
NSE
SGMD.V
Salona Global Medical Device Corporation.
0.22 CAD
TSX
HTL.V
Hamilton Thorne Ltd..
1.45 CAD
TSX

Biežāk uzdotie jautājumi

Kas ir Abiomed, Inc. (ABMD) kopējie aktīvi?

Abiomed, Inc. (ABMD) kopējie aktīvi ir 1673393000.000.

Kādi ir uzņēmuma gada ieņēmumi?

Gada ieņēmumi ir 543070000.000.

Kāda ir uzņēmuma peļņas norma?

Uzņēmuma peļņas norma ir 0.818.

Kāda ir uzņēmuma brīvā naudas plūsma?

Brīvā naudas plūsma ir 5.493.

Kāda ir uzņēmuma neto peļņas norma?

Neto peļņas norma ir 0.132.

Kādi ir uzņēmuma kopējie ieņēmumi?

Kopējie ieņēmumi ir 0.361.

Kāda ir Abiomed, Inc. (ABMD) tīrā peļņa (tīrie ienākumi)?

Tīrā peļņa (tīrie ienākumi) ir 136505000.000.

Kāds ir uzņēmuma kopējais parāds?

Kopējais parāds ir 0.000.

Kāds ir pamatdarbības izdevumu skaits?

Darbības izdevumi ir 586889000.000.

Kāds ir uzņēmuma skaidrās naudas rādītājs?

Uzņēmuma nauda ir 182335000.000.